Patents by Inventor Rafael Davalos
Rafael Davalos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240318111Abstract: Various examples are provided related to nanofiber networks that can mimic in vivo physiology. In one example, a scaffold includes a nanofiber membrane extending across a scaffold opening. The nanofiber membrane can include a stack of nanofiber layers that include nanofibers disposed with a controlled orientation or direction and a controlled spacing. The nanofibers are cross-linked with nanofibers of an adjacent nanofiber layer. The scaffold can be incorporated into a transwell insert or plate. In another example, a microfluidic chip can include a first channel layer with a first fluid channel; a second channel layer comprising a second fluid channel; and a scaffold including a nanofiber membrane disposed between the first and second channel layers. The first and second channels cross each other.Type: ApplicationFiled: June 25, 2022Publication date: September 26, 2024Inventors: Philip Graybill, Rafael Davalos, Aniket Jana, Amrinder Nain
-
Patent number: 12076719Abstract: Described herein are aspects of a microfluidic separation and assay system that can include a microfluidic contactless dielectrophoretic (cDEP) device, a microfluidic concentrator, and a microfluidic assay chamber. In some aspects, microfluidic separation and assay system can be included on a single microfluidic chip. Also described herein are methods of using the microfluidic separation and assay system described herein.Type: GrantFiled: March 12, 2019Date of Patent: September 3, 2024Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Temple Douglas, Philip Melvin Graybill, Rafael Davalos
-
Patent number: 11607537Abstract: This disclosure describes the methods, devices, and systems of treating diseased tissue with integrated nanosecond pulse irreversible electroporation. Methods and systems as disclosed provide MRI compatible shielded electrodes and electrode leads to prevent emanating radiofrequency noise and improve image quality, disconnecting the electrode from the cable linkage to the pulse generator reduce electromagnetic interference and image artifacts, placing electrodes strategically within a guide cannula to minimize distortion from heterogeneities or maximize ablation within the tissue, utilizing conductive fluids, innate or external, such as cerebral spinal fluid or grounding pads to provide a pathway for current return, and for timing of the electrical waveforms with inherent brain electrical activity.Type: GrantFiled: December 5, 2018Date of Patent: March 21, 2023Assignees: Virginia Tech Intellectual Properties, Inc., VoltMed, Inc.Inventors: Eduardo Latouche, Samuel Lesko, Lucy Epshteyn, Christopher B. Arena, John H. Rossmeisl, Jr., Melvin Lorenzo, Rafael Davalos
-
Publication number: 20220290183Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to methods for modifying cells such as, for example, changing shape, cell force, and/or modifying structural integrity of the cells. In a further aspect, the disclosure relates to controlling membrane permeability in cells by applying an electric current, where the cells are in contact with a polymeric nanofiber array and wherein direction and voltage of the electric current can be modified to induce the desired cellular response. In some aspects, the method results in higher survivability for cells during electroporation, greater permeability to molecules and/or drugs of different sizes, and greater transfection efficiencies for rare primary cells.Type: ApplicationFiled: August 28, 2020Publication date: September 15, 2022Inventors: Rafael DAVALOS, Amrinder NAIN
-
Publication number: 20210370292Abstract: Described herein are aspects of a microfluidic separation and assay system that can include a microfluidic contactless dielectrophoretic (cDEP) device, a microfluidic concentrator, and a microfluidic assay chamber. In some aspects, microfluidic separation and assay system can be included on a single microfluidic chip. Also described herein are methods of using the microfluidic separation and assay system described herein.Type: ApplicationFiled: March 12, 2019Publication date: December 2, 2021Inventors: Temple DOUGLAS, Phillip Melvin GRAYBILL, Rafael DAVALOS
-
Patent number: 11033321Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: GrantFiled: October 15, 2018Date of Patent: June 15, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Rafael Davalos, Boris Rubinsky
-
Publication number: 20190232048Abstract: This disclosure describes the methods, devices, and systems of treating diseased tissue with integrated nanosecond pulse irreversible electroporation. Methods and systems as disclosed provide MRI compatible shielded electrodes and electrode leads to prevent emanating radiofrequency noise and improve image quality, disconnecting the electrode from the cable linkage to the pulse generator reduce electromagnetic interference and image artifacts, placing electrodes strategically within a guide cannula to minimize distortion from heterogeneities or maximize ablation within the tissue, utilizing conductive fluids, innate or external, such as cerebral spinal fluid or grounding pads to provide a pathway for current return, and for timing of the electrical waveforms with inherent brain electrical activity.Type: ApplicationFiled: December 5, 2018Publication date: August 1, 2019Inventors: EDUARDO LATOUCHE, SAMUEL LESKO, LUCY EPSHTEYN, CHRISTOPHER ARENA, JOHN ROSSMEISL, MELVIN LORENZO, RAFAEL DAVALOS
-
Publication number: 20190046255Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: ApplicationFiled: October 15, 2018Publication date: February 14, 2019Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Rafael Davalos, BORIS Rubinsky
-
Patent number: 10117701Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: GrantFiled: March 5, 2015Date of Patent: November 6, 2018Assignee: The Regents of the University of CaliforniaInventors: Rafael Davalos, Boris Rubinsky
-
Publication number: 20150173824Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: ApplicationFiled: March 5, 2015Publication date: June 25, 2015Inventors: RAFAEL DAVALOS, BORIS RUBINSKY
-
Patent number: 9005189Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: GrantFiled: July 11, 2012Date of Patent: April 14, 2015Assignee: The Regents of the University of CaliforniaInventors: Rafael Davalos, Boris Rubinsky
-
Patent number: 8926606Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) or supra-poration to cause cell death in treated tumors. In embodiments, the methods comprise the integration of ultra-short electric pulses, both temporally and spatially, to achieve the desired modality of cell death.Type: GrantFiled: April 9, 2010Date of Patent: January 6, 2015Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Rafael Davalos, Christopher B. Arena, John Caldwell
-
Publication number: 20120277741Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: ApplicationFiled: July 11, 2012Publication date: November 1, 2012Inventors: RAFAEL DAVALOS, Boris Rubinsky
-
Patent number: 8282631Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: GrantFiled: September 20, 2011Date of Patent: October 9, 2012Assignee: The Regents of the University of CaliforniaInventors: Rafael Davalos, Boris Rubinsky
-
Publication number: 20120071874Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: ApplicationFiled: September 20, 2011Publication date: March 22, 2012Inventors: Rafael Davalos, Boris Rubinsky
-
Patent number: 8048067Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: GrantFiled: December 21, 2004Date of Patent: November 1, 2011Assignee: The Regents of the University of CaliforniaInventors: Rafael Davalos, Boris Rubinsky
-
Publication number: 20100261994Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) or supra-poration to cause cell death in treated tumors. In embodiments, the methods comprise the integration of ultra-short electric pulses, both temporally and spatially, to achieve the desired modality of cell death.Type: ApplicationFiled: April 9, 2010Publication date: October 14, 2010Inventors: Rafael DAVALOS, Christopher B. ARENA, John CALDWELL
-
Publication number: 20100030211Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.Type: ApplicationFiled: June 24, 2009Publication date: February 4, 2010Inventors: Rafael Davalos, Paulo A. Garcia, John H. Rossmeisl, John L. Robertson, Robert E. Neal
-
Publication number: 20070043345Abstract: A new method for the ablation of undesirable tissue such as cells of a cancerous or non-cancerous tumor is disclosed. It involves the placement of electrodes into or near the vicinity of the undesirable tissue through the application of electrical pulses causing irreversible electroporation of the cells throughout the entire area of the undesirable tissue. The electric pulses irreversibly permeate the cell membranes, thereby invoking cell death. The irreversibly permeabilized cells are left in situ and are removed by the body immune system. The amount of tissue ablation achievable through the use of irreversible electroporation without inducing thermal damage is considerable.Type: ApplicationFiled: December 21, 2004Publication date: February 22, 2007Inventors: Rafael Davalos, Boris Rubinsky